Proteolysis: A Biological Process Adapted in Drug Delivery, Therapy, and Imaging

被引:103
作者
Law, Benedict [1 ]
Tung, Ching-Hsuan [2 ]
机构
[1] N Dakota State Univ, Dept Pharmaceut Sci, Fargo, ND 58105 USA
[2] Methodist Hosp, Res Inst, Weill Cornell Med Coll, Houston, TX 77030 USA
关键词
L-LEUCYL-DOXORUBICIN; TUMOR-ACTIVATED PRODRUG; TARGETED THERAPY; MATRIX METALLOPROTEINASES; GALACTOSYLATED LIPOSOMES; PHOTODYNAMIC THERAPY; ANTICANCER PRODRUGS; CELLULAR UPTAKE; BETA-LACTAMASE; AMINO-ACID;
D O I
10.1021/bc800500a
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In many diseases, protease expressions are found deregulated when compared with them at the healthy states. The unique ability to hydrolyze protein amide bonds has made those deregulated proteases attractive biological triggers in drug development. Proteolysis has been widely applied in pro-drug design to achieve favorable pharmacokinetics. Controlled drug delivery systems are also reported by incorporating protease-sensitive motifs onto bio-, inorganic-, or organic- materials, In addition, protease responsive molecular probes are developed for in vitro bioanalysis and in vivo diagnostic imaging. This review focuses on various proteolysis-dependent approaches to drug delivery, therapy, and imaging. References are selected to illustrate the concepts and demonstrate the potentials of these enzyme-responsive strategies.
引用
收藏
页码:1683 / 1695
页数:13
相关论文
共 151 条
[1]   Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity [J].
Albright, CF ;
Graciani, N ;
Han, W ;
Yue, E ;
Stein, R ;
Lai, ZH ;
Diamond, M ;
Dowling, R ;
Grimminger, L ;
Zhang, SY ;
Behrens, D ;
Musselman, A ;
Bruckner, R ;
Zhang, MZ ;
Jiang, X ;
Hu, D ;
Higley, A ;
DiMeo, S ;
Rafalski, M ;
Mandlekar, S ;
Car, B ;
Yeleswaram, S ;
Stern, A ;
Copeland, RA ;
Combs, A ;
Seitz, SP ;
Trainor, GL ;
Taub, R ;
Huang, P ;
Oliff, A .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) :751-760
[2]   Tumour endoproteases: the cutting edge of cancer drug delivery? [J].
Atkinson, J. M. ;
Siller, C. S. ;
Gill, J. H. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (07) :1344-1352
[3]   SYNTHESIS AND FUNCTIONAL-EVALUATION OF A PEPTIDE DERIVATIVE OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE [J].
BALAJTHY, Z ;
ARADI, J ;
KISS, IT ;
ELODI, P .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (18) :3344-3349
[4]   AMINO-ACID AND DIPEPTIDE DERIVATIVES OF DAUNORUBICIN .2. CELLULAR PHARMACOLOGY AND ANTI-TUMOR ACTIVITY ON L1210 LEUKEMIC-CELLS INVITRO AND INVIVO [J].
BAURAIN, R ;
MASQUELIER, M ;
DEPREZDECAMPENEERE, D ;
TROUET, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1980, 23 (11) :1171-1174
[5]   THE ANTITUMOR EFFECTS OF THE PRODRUGS N-L-LEUCYL-DOXORUBICIN AND VINBLASTINE-ISOLEUCINATE IN HUMAN OVARIAN-CANCER XENOGRAFTS [J].
BOVEN, E ;
HENDRIKS, HR ;
ERKELENS, CAM ;
PINEDO, HM .
BRITISH JOURNAL OF CANCER, 1992, 66 (06) :1044-1047
[6]   The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts [J].
Breistol, K ;
Hendriks, HR ;
Berger, DP ;
Langdon, SP ;
Fiebig, HH ;
Fodstad, O .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) :1602-1606
[7]   Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug [J].
Breistol, K ;
Hendriks, HR ;
Fodstad, O .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (07) :1143-1149
[8]   In vivo molecular target assessment of matrix metalloproteinase inhibition [J].
Bremer, C ;
Tung, CH ;
Weissleder, R .
NATURE MEDICINE, 2001, 7 (06) :743-748
[9]   Optical imaging of matrix metalloproteinase-2 activity in tumors: Feasibility study in a mouse model [J].
Bremer, C ;
Bredow, S ;
Mahmood, U ;
Weissleder, R ;
Tung, CH .
RADIOLOGY, 2001, 221 (02) :523-529
[10]   Enzymatic stabilization of gelatin-based scaffolds [J].
Broderick, EP ;
O'Halloran, DM ;
Rochev, YA ;
Griffin, M ;
Collighan, RJ ;
Pandit, AS .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS, 2005, 72B (01) :37-42